Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pyrotinib Maleate combine with Docetaxel
Sponsor: Zhejiang Cancer Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.